BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

407 related articles for article (PubMed ID: 28562336)

  • 1. Synergistic targeting of malignant pleural mesothelioma cells by MDM2 inhibitors and TRAIL agonists.
    Urso L; Cavallari I; Silic-Benussi M; Biasini L; Zago G; Calabrese F; Conte PF; Ciminale V; Pasello G
    Oncotarget; 2017 Jul; 8(27):44232-44241. PubMed ID: 28562336
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mdm2 protein expression is strongly associated with survival in malignant pleural mesothelioma.
    Mairinger FD; Walter RF; Ting S; Vollbrecht C; Kollmeier J; Griff S; Hager T; Mairinger T; Christoph DC; Theegarten D; Schmid KW; Wohlschlaeger J
    Future Oncol; 2014 May; 10(6):995-1005. PubMed ID: 24941985
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PI3 Kinase Pathway and MET Inhibition is Efficacious in Malignant Pleural Mesothelioma.
    Kanteti R; Riehm JJ; Dhanasingh I; Lennon FE; Mirzapoiazova T; Mambetsariev B; Kindler HL; Salgia R
    Sci Rep; 2016 Sep; 6():32992. PubMed ID: 27623107
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacological targeting of p53 through RITA is an effective antitumoral strategy for malignant pleural mesothelioma.
    Di Marzo D; Forte IM; Indovina P; Di Gennaro E; Rizzo V; Giorgi F; Mattioli E; Iannuzzi CA; Budillon A; Giordano A; Pentimalli F
    Cell Cycle; 2014; 13(4):652-65. PubMed ID: 24345738
    [TBL] [Abstract][Full Text] [Related]  

  • 5. JQ1, a BET Inhibitor, Synergizes with Cisplatin and Induces Apoptosis in Highly Chemoresistant Malignant Pleural Mesothelioma Cells.
    Zanellato I; Colangelo D; Osella D
    Curr Cancer Drug Targets; 2018; 18(8):816-828. PubMed ID: 28669341
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MicroRNA-215-5p Treatment Suppresses Mesothelioma Progression via the MDM2-p53-Signaling Axis.
    Singh A; Bhattacharyya N; Srivastava A; Pruett N; Ripley RT; Schrump DS; Hoang CD
    Mol Ther; 2019 Sep; 27(9):1665-1680. PubMed ID: 31227395
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intracellular lactate-mediated induction of estrogen receptor beta (ERβ) in biphasic malignant pleural mesothelioma cells.
    Manente AG; Pinton G; Zonca S; Cilli M; Rinaldi M; Daga A; Nilsson S; Moro L
    Oncotarget; 2015 Sep; 6(28):25121-34. PubMed ID: 26208479
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Trabectedin Is Active against Malignant Pleural Mesothelioma Cell and Xenograft Models and Synergizes with Chemotherapy and Bcl-2 Inhibition In Vitro.
    Hoda MA; Pirker C; Dong Y; Schelch K; Heffeter P; Kryeziu K; van Schoonhoven S; Klikovits T; Laszlo V; Rozsas A; Ozsvar J; Klepetko W; Döme B; Grusch M; Hegedüs B; Berger W
    Mol Cancer Ther; 2016 Oct; 15(10):2357-2369. PubMed ID: 27512118
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sorafenib inhibits ERK1/2 and MCL-1(L) phosphorylation levels resulting in caspase-independent cell death in malignant pleural mesothelioma.
    Katz SI; Zhou L; Chao G; Smith CD; Ferrara T; Wang W; Dicker DT; El-Deiry WS
    Cancer Biol Ther; 2009 Dec; 8(24):2406-16. PubMed ID: 20038816
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MDM2 is an important prognostic and predictive factor for platin-pemetrexed therapy in malignant pleural mesotheliomas and deregulation of P14/ARF (encoded by CDKN2A) seems to contribute to an MDM2-driven inactivation of P53.
    Walter RF; Mairinger FD; Ting S; Vollbrecht C; Mairinger T; Theegarten D; Christoph DC; Schmid KW; Wohlschlaeger J
    Br J Cancer; 2015 Mar; 112(5):883-90. PubMed ID: 25668009
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synergistic antitumor activity of recombinant human Apo2L/tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) in combination with carboplatin and pemetrexed in malignant pleural mesothelioma.
    Pasello G; Urso L; Silic-Benussi M; Schiavon M; Cavallari I; Marulli G; Nannini N; Rea F; Ciminale V; Favaretto A
    J Thorac Oncol; 2014 Jul; 9(7):1008-1017. PubMed ID: 24922007
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MDM2 and HIF1alpha expression levels in different histologic subtypes of malignant pleural mesothelioma: correlation with pathological and clinical data.
    Pasello G; Urso L; Mencoboni M; Grosso F; Ceresoli GL; Lunardi F; Vuljan SE; Bertorelle R; Sacchetto V; Ciminale V; Rea F; Favaretto A; Conte P; Calabrese F
    Oncotarget; 2015 Dec; 6(39):42053-66. PubMed ID: 26544728
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In Vitro and In Vivo Antitumor Activity of [Pt(O,O'-acac)(γ-acac)(DMS)] in Malignant Pleural Mesothelioma.
    Muscella A; Vetrugno C; Cossa LG; Antonaci G; De Nuccio F; De Pascali SA; Fanizzi FP; Marsigliante S
    PLoS One; 2016; 11(11):e0165154. PubMed ID: 27806086
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mithramycin Depletes Specificity Protein 1 and Activates p53 to Mediate Senescence and Apoptosis of Malignant Pleural Mesothelioma Cells.
    Rao M; Atay SM; Shukla V; Hong Y; Upham T; Ripley RT; Hong JA; Zhang M; Reardon E; Fetsch P; Miettinen M; Li X; Peer CJ; Sissung T; Figg WD; De Rienzo A; Bueno R; Schrump DS
    Clin Cancer Res; 2016 Mar; 22(5):1197-210. PubMed ID: 26459178
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antagonists of growth hormone-releasing hormone (GHRH) inhibit the growth of human malignant pleural mesothelioma.
    Villanova T; Gesmundo I; Audrito V; Vitale N; Silvagno F; Musuraca C; Righi L; Libener R; Riganti C; Bironzo P; Deaglio S; Papotti M; Cai R; Sha W; Ghigo E; Schally AV; Granata R
    Proc Natl Acad Sci U S A; 2019 Feb; 116(6):2226-2231. PubMed ID: 30659154
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TRAIL and proteasome inhibitors combination induces a robust apoptosis in human malignant pleural mesothelioma cells through Mcl-1 and Akt protein cleavages.
    Yuan BZ; Chapman J; Ding M; Wang J; Jiang B; Rojanasakul Y; Reynolds SH
    BMC Cancer; 2013 Mar; 13():140. PubMed ID: 23517112
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An MDM2 inhibitor achieves synergistic cytotoxic effects with adenoviruses lacking E1B55kDa gene on mesothelioma with the wild-type p53 through augmenting NFI expression.
    Nguyen TTT; Shingyoji M; Hanazono M; Zhong B; Morinaga T; Tada Y; Shimada H; Hiroshima K; Tagawa M
    Cell Death Dis; 2021 Jul; 12(7):663. PubMed ID: 34230456
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting of the Hedgehog signal transduction pathway suppresses survival of malignant pleural mesothelioma cells in vitro.
    You M; Varona-Santos J; Singh S; Robbins DJ; Savaraj N; Nguyen DM
    J Thorac Cardiovasc Surg; 2014 Jan; 147(1):508-16. PubMed ID: 24094913
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Functional Analysis of the Adrenomedullin Pathway in Malignant Pleural Mesothelioma.
    Greillier L; Tounsi A; Berenguer-Daizé C; Dussault N; Delfino C; Benyahia Z; Cayol M; Mabrouk K; Garcia S; Martin PM; Barlesi F; Ouafik L
    J Thorac Oncol; 2016 Jan; 11(1):94-107. PubMed ID: 26762744
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Apoptosis by [Pt(O,O'-acac)(γ-acac)(DMS)] requires PKC-δ mediated p53 activation in malignant pleural mesothelioma.
    Muscella A; Vetrugno C; Cossa LG; Antonaci G; Barca A; De Pascali SA; Fanizzi FP; Marsigliante S
    PLoS One; 2017; 12(7):e0181114. PubMed ID: 28704484
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.